1. Home
  2. SLS

SLS

SELLAS Life Sciences Group Inc.

Logo SELLAS Life Sciences Group Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Founded: 2012 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 75.4M IPO Year: N/A
Target Price: $3.00 AVG Volume (30 days): 1.4M
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.34 EPS Growth: N/A
52 Week Low/High: $0.50 - $1.91 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: